- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT04527549
A dabrafenib és a trametinib tesztelése hidroxiklorokinnal vagy anélkül a BRAF V600E/K melanoma IIIC vagy IV stádiumában
A BAMM2 (BRAF, autofágia, MEK gátlás melanomában) tanulmány: Randomizált kettős vak II. fázisú vizsgálat dabrafenibről és trametinibről hidroxiklorokinnal vagy anélkül, fejlett BRAF V600E/K melanomában
This phase II trial investigates how well adding hydroxychloroquine to the standard treatment of dabrafenib and trametinib works to overcome resistance and delay disease progression in treating patients with stage IIIC or IV BRAF V600E/K melanoma. Hydroxychloroquine may cause cell death in tumor cells that rely on a process called "autophagy" for survival. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving hydroxychloroquine together with dabrafenib and trametinib may work better than dabrafenib and trametinib alone to shrink and stabilize the cancer.
A tanulmány áttekintése
Állapot
Körülmények
Részletes leírás
PRIMARY OBJECTIVE:
I. To determine the rate of one year progression-free survival (PFS) when hydroxychloroquine sulfate (hydroxychloroquine) or placebo is added to dabrafenib mesylate (dabrafenib) and trametinib dimethyl sulfoxide (trametinib) in advanced BRAFV600E/K melanoma with elevated lactate dehydrogenase (LDH).
SECONDARY OBJECTIVES:
I. To compare the PFS of both arms. II. To evaluate the best overall response rate by treatment arm. III. To evaluate the complete response (CR) rate by treatment arm. IV. To evaluate the adverse event rate by treatment arm. V. To evaluate overall survival (OS) by treatment arm.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive dabrafenib mesylate orally (PO) twice daily (BID), trametinib dimethyl sulfoxide PO once daily (QD), and hydroxychloroquine sulfate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
ARM B: Patients receive dabrafenib mesylate PO BID, trametinib dimethyl sulfoxide PO QD, and placebo PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 1 year.
Tanulmány típusa
Beiratkozás (Tényleges)
Fázis
- 2. fázis
Kapcsolatok és helyek
Tanulmányi helyek
-
-
Alaska
-
Anchorage, Alaska, Egyesült Államok, 98508
- Anchorage Associates in Radiation Medicine
-
Anchorage, Alaska, Egyesült Államok, 99508
- Alaska Breast Care and Surgery LLC
-
Anchorage, Alaska, Egyesült Államok, 99508
- Alaska Oncology and Hematology LLC
-
Anchorage, Alaska, Egyesült Államok, 99508
- Alaska Women's Cancer Care
-
Anchorage, Alaska, Egyesült Államok, 99508
- Anchorage Oncology Centre
-
Anchorage, Alaska, Egyesült Államok, 99508
- Katmai Oncology Group
-
Anchorage, Alaska, Egyesült Államok, 99508
- Providence Alaska Medical Center
-
Anchorage, Alaska, Egyesült Államok, 99504
- Anchorage Radiation Therapy Center
-
-
Arizona
-
Phoenix, Arizona, Egyesült Államok, 85054
- Mayo Clinic Hospital in Arizona
-
Phoenix, Arizona, Egyesült Államok, 85004
- Cancer Center at Saint Joseph's
-
Scottsdale, Arizona, Egyesült Államok, 85259
- Mayo Clinic in Arizona
-
-
Arkansas
-
Fort Smith, Arkansas, Egyesült Államok, 72903
- Mercy Hospital Fort Smith
-
Hot Springs, Arkansas, Egyesült Államok, 71913
- CHI Saint Vincent Cancer Center Hot Springs
-
-
California
-
Arroyo Grande, California, Egyesült Államok, 93420
- Mission Hope Medical Oncology - Arroyo Grande
-
Burbank, California, Egyesült Államok, 91505
- Providence Saint Joseph Medical Center/Disney Family Cancer Center
-
Los Angeles, California, Egyesült Államok, 90048
- Cedars Sinai Medical Center
-
San Luis Obispo, California, Egyesült Államok, 93401
- Pacific Central Coast Health Center-San Luis Obispo
-
Santa Maria, California, Egyesült Államok, 93444
- Mission Hope Medical Oncology - Santa Maria
-
-
Colorado
-
Colorado Springs, Colorado, Egyesült Államok, 80907
- Penrose-Saint Francis Healthcare
-
Colorado Springs, Colorado, Egyesült Államok, 80907
- Rocky Mountain Cancer Centers-Penrose
-
Colorado Springs, Colorado, Egyesült Államok, 80923
- Saint Francis Cancer Center
-
Denver, Colorado, Egyesült Államok, 80210
- Porter Adventist Hospital
-
Durango, Colorado, Egyesült Államok, 81301
- Mercy Medical Center
-
Durango, Colorado, Egyesült Államok, 81301
- Southwest Oncology PC
-
Lakewood, Colorado, Egyesült Államok, 80228
- Saint Anthony Hospital
-
Littleton, Colorado, Egyesült Államok, 80122
- Littleton Adventist Hospital
-
Longmont, Colorado, Egyesült Államok, 80501
- Longmont United Hospital
-
Longmont, Colorado, Egyesült Államok, 80501
- Rocky Mountain Cancer Centers-Longmont
-
Parker, Colorado, Egyesült Államok, 80138
- Parker Adventist Hospital
-
Pueblo, Colorado, Egyesült Államok, 81004
- Saint Mary Corwin Medical Center
-
-
Delaware
-
Frankford, Delaware, Egyesült Államok, 19945
- Beebe South Coastal Health Campus
-
Lewes, Delaware, Egyesült Államok, 19958
- Beebe Medical Center
-
Newark, Delaware, Egyesült Államok, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Egyesült Államok, 19713
- Delaware Clinical and Laboratory Physicians PA
-
Newark, Delaware, Egyesült Államok, 19713
- Medical Oncology Hematology Consultants PA
-
Newark, Delaware, Egyesült Államok, 19718
- Christiana Care Health System-Christiana Hospital
-
Rehoboth Beach, Delaware, Egyesült Államok, 19971
- Beebe Health Campus
-
Seaford, Delaware, Egyesült Államok, 19973
- TidalHealth Nanticoke / Allen Cancer Center
-
Wilmington, Delaware, Egyesült Államok, 19801
- Christiana Care Health System-Wilmington Hospital
-
-
District of Columbia
-
Washington D.C., District of Columbia, Egyesült Államok, 20007
- MedStar Georgetown University Hospital
-
-
Florida
-
Aventura, Florida, Egyesült Államok, 33180
- UM Sylvester Comprehensive Cancer Center at Aventura
-
Coral Gables, Florida, Egyesült Államok, 33146
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Deerfield Beach, Florida, Egyesült Államok, 33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Miami, Florida, Egyesült Államok, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami, Florida, Egyesült Államok, 33176
- UM Sylvester Comprehensive Cancer Center at Kendall
-
Plantation, Florida, Egyesült Államok, 33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
-
Idaho
-
Boise, Idaho, Egyesült Államok, 83712
- Saint Luke's Cancer Institute - Boise
-
Fruitland, Idaho, Egyesült Államok, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Egyesült Államok, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Egyesült Államok, 83686
- Saint Luke's Cancer Institute - Nampa
-
Twin Falls, Idaho, Egyesült Államok, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Alton, Illinois, Egyesült Államok, 62002
- Saint Anthony's Health
-
Aurora, Illinois, Egyesült Államok, 60504
- Rush - Copley Medical Center
-
Burr Ridge, Illinois, Egyesült Államok, 60527
- Loyola Center for Health at Burr Ridge
-
Danville, Illinois, Egyesült Államok, 61832
- Carle on Vermilion
-
Effingham, Illinois, Egyesült Államok, 62401
- Carle Physician Group-Effingham
-
Homer Glen, Illinois, Egyesült Államok, 60491
- Loyola Medicine Homer Glen
-
Mattoon, Illinois, Egyesült Államok, 61938
- Carle Physician Group-Mattoon/Charleston
-
Maywood, Illinois, Egyesült Államok, 60153
- Loyola University Medical Center
-
Melrose Park, Illinois, Egyesült Államok, 60160
- Marjorie Weinberg Cancer Center at Loyola-Gottlieb
-
Mount Vernon, Illinois, Egyesült Államok, 62864
- Good Samaritan Regional Health Center
-
Urbana, Illinois, Egyesült Államok, 61801
- Carle Cancer Center
-
Urbana, Illinois, Egyesült Államok, 61801
- The Carle Foundation Hospital
-
Yorkville, Illinois, Egyesült Államok, 60560
- Rush-Copley Healthcare Center
-
-
Indiana
-
Richmond, Indiana, Egyesült Államok, 47374
- Reid Health
-
-
Iowa
-
Ames, Iowa, Egyesült Államok, 50010
- McFarland Clinic PC - Ames
-
Ames, Iowa, Egyesült Államok, 50010
- Mary Greeley Medical Center
-
Boone, Iowa, Egyesült Államok, 50036
- McFarland Clinic PC-Boone
-
Carroll, Iowa, Egyesült Államok, 51401
- Saint Anthony Regional Hospital
-
Clive, Iowa, Egyesült Államok, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Egyesült Államok, 50325
- Medical Oncology and Hematology Associates-West Des Moines
-
Council Bluffs, Iowa, Egyesült Államok, 51503
- Alegent Health Mercy Hospital
-
Creston, Iowa, Egyesült Államok, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, Egyesült Államok, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Egyesült Államok, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Egyesült Államok, 50309
- Medical Oncology and Hematology Associates-Des Moines
-
Des Moines, Iowa, Egyesült Államok, 50314
- Broadlawns Medical Center
-
Des Moines, Iowa, Egyesült Államok, 50314
- Mission Cancer and Blood - Laurel
-
Des Moines, Iowa, Egyesült Államok, 50316
- Iowa Lutheran Hospital
-
Fort Dodge, Iowa, Egyesült Államok, 50501
- McFarland Clinic PC-Trinity Cancer Center
-
Fort Dodge, Iowa, Egyesült Államok, 50501
- Trinity Regional Medical Center
-
Jefferson, Iowa, Egyesült Államok, 50129
- McFarland Clinic PC-Jefferson
-
Marshalltown, Iowa, Egyesült Államok, 50158
- McFarland Clinic PC-Marshalltown
-
West Des Moines, Iowa, Egyesült Államok, 50266-7700
- Methodist West Hospital
-
West Des Moines, Iowa, Egyesült Államok, 50266
- Mercy Medical Center-West Lakes
-
-
Kansas
-
Garden City, Kansas, Egyesült Államok, 67846
- Central Care Cancer Center - Garden City
-
Great Bend, Kansas, Egyesült Államok, 67530
- Central Care Cancer Center - Great Bend
-
-
Kentucky
-
Bardstown, Kentucky, Egyesült Államok, 40004
- Flaget Memorial Hospital
-
Corbin, Kentucky, Egyesült Államok, 40701
- Commonwealth Cancer Center-Corbin
-
Lexington, Kentucky, Egyesült Államok, 40504
- Saint Joseph Radiation Oncology Resource Center
-
Lexington, Kentucky, Egyesült Államok, 40509
- Saint Joseph Hospital East
-
London, Kentucky, Egyesült Államok, 40741
- Saint Joseph London
-
Louisville, Kentucky, Egyesült Államok, 40202
- Jewish Hospital
-
Louisville, Kentucky, Egyesült Államok, 40245
- UofL Health Medical Center Northeast
-
Louisville, Kentucky, Egyesült Államok, 40215
- Saints Mary and Elizabeth Hospital
-
Shepherdsville, Kentucky, Egyesült Államok, 40165
- Jewish Hospital Medical Center South
-
-
Maryland
-
Baltimore, Maryland, Egyesült Államok, 21237
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute
-
-
Minnesota
-
Rochester, Minnesota, Egyesült Államok, 55905
- Mayo Clinic in Rochester
-
-
Missouri
-
Ballwin, Missouri, Egyesült Államok, 63011
- Saint Louis Cancer and Breast Institute-Ballwin
-
Bolivar, Missouri, Egyesült Államok, 65613
- Central Care Cancer Center - Bolivar
-
Branson, Missouri, Egyesült Államok, 65616
- Cox Cancer Center Branson
-
Joplin, Missouri, Egyesült Államok, 64804
- Freeman Health System
-
Joplin, Missouri, Egyesült Államok, 64804
- Mercy Hospital Joplin
-
Rolla, Missouri, Egyesült Államok, 65401
- Delbert Day Cancer Institute at PCRMC
-
Rolla, Missouri, Egyesült Államok, 65401
- Mercy Clinic-Rolla-Cancer and Hematology
-
Saint Joseph, Missouri, Egyesült Államok, 64506
- Heartland Regional Medical Center
-
Springfield, Missouri, Egyesült Államok, 65807
- CoxHealth South Hospital
-
Springfield, Missouri, Egyesült Államok, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Egyesült Államok, 63141
- Mercy Hospital Saint Louis
-
St Louis, Missouri, Egyesült Államok, 63128
- Mercy Hospital South
-
St Louis, Missouri, Egyesült Államok, 63109
- Saint Louis Cancer and Breast Institute-South City
-
Washington, Missouri, Egyesült Államok, 63090
- Mercy Hospital Washington
-
-
Montana
-
Missoula, Montana, Egyesült Államok, 59802
- Saint Patrick Hospital - Community Hospital
-
-
Nebraska
-
Grand Island, Nebraska, Egyesült Államok, 68803
- CHI Health Saint Francis
-
Kearney, Nebraska, Egyesült Államok, 68847
- CHI Health Good Samaritan
-
Lincoln, Nebraska, Egyesült Államok, 68510
- Saint Elizabeth Regional Medical Center
-
Omaha, Nebraska, Egyesült Államok, 68124
- Alegent Health Bergan Mercy Medical Center
-
Omaha, Nebraska, Egyesült Államok, 68122
- Alegent Health Immanuel Medical Center
-
Omaha, Nebraska, Egyesült Államok, 68130
- Alegent Health Lakeside Hospital
-
Omaha, Nebraska, Egyesült Államok, 68131
- Creighton University Medical Center
-
Papillion, Nebraska, Egyesült Államok, 68046
- Midlands Community Hospital
-
-
New York
-
New York, New York, Egyesült Államok, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
-
Ohio
-
Beavercreek, Ohio, Egyesült Államok, 45431
- Indu and Raj Soin Medical Center
-
Boardman, Ohio, Egyesült Államok, 44512
- Saint Elizabeth Boardman Hospital
-
Centerville, Ohio, Egyesült Államok, 45459
- Miami Valley Hospital South
-
Centerville, Ohio, Egyesült Államok, 45459
- Dayton Physicians LLC-Miami Valley South
-
Cincinnati, Ohio, Egyesült Államok, 45220
- Good Samaritan Hospital - Cincinnati
-
Cincinnati, Ohio, Egyesült Államok, 45242
- Bethesda North Hospital
-
Cincinnati, Ohio, Egyesült Államok, 45236
- Oncology Hematology Care Inc-Kenwood
-
Cincinnati, Ohio, Egyesült Államok, 45247
- TriHealth Cancer Institute-Westside
-
Cincinnati, Ohio, Egyesült Államok, 45255
- TriHealth Cancer Institute-Anderson
-
Dayton, Ohio, Egyesült Államok, 45409
- Miami Valley Hospital
-
Dayton, Ohio, Egyesült Államok, 45415
- Dayton Physician LLC-Miami Valley Hospital North
-
Dayton, Ohio, Egyesült Államok, 45415
- Miami Valley Hospital North
-
Findlay, Ohio, Egyesült Államok, 45840
- Blanchard Valley Hospital
-
Findlay, Ohio, Egyesült Államok, 45840
- Armes Family Cancer Center
-
Findlay, Ohio, Egyesült Államok, 45840
- Orion Cancer Care
-
Franklin, Ohio, Egyesült Államok, 45005-1066
- Atrium Medical Center-Middletown Regional Hospital
-
Franklin, Ohio, Egyesült Államok, 45005
- Dayton Physicians LLC-Atrium
-
Greenville, Ohio, Egyesült Államok, 45331
- Wayne Hospital
-
Greenville, Ohio, Egyesült Államok, 45331
- Dayton Physicians LLC-Wayne
-
Kettering, Ohio, Egyesült Államok, 45429
- Kettering Medical Center
-
Kettering, Ohio, Egyesült Államok, 45409
- Greater Dayton Cancer Center
-
Springfield, Ohio, Egyesült Államok, 45505
- Springfield Regional Medical Center
-
Springfield, Ohio, Egyesült Államok, 45504
- Springfield Regional Cancer Center
-
Troy, Ohio, Egyesült Államok, 45373
- Upper Valley Medical Center
-
Troy, Ohio, Egyesült Államok, 45373
- Dayton Physicians LLC-Upper Valley
-
Warren, Ohio, Egyesült Államok, 44484
- Saint Joseph Warren Hospital
-
Youngstown, Ohio, Egyesült Államok, 44501
- Saint Elizabeth Youngstown Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Egyesült Államok, 73120
- Mercy Hospital Oklahoma City
-
-
Oregon
-
Bend, Oregon, Egyesült Államok, 97701
- Saint Charles Health System
-
Clackamas, Oregon, Egyesült Államok, 97015
- Clackamas Radiation Oncology Center
-
Clackamas, Oregon, Egyesült Államok, 97015
- Providence Cancer Institute Clackamas Clinic
-
Coos Bay, Oregon, Egyesült Államok, 97420
- Bay Area Hospital
-
Newberg, Oregon, Egyesült Államok, 97132
- Providence Newberg Medical Center
-
Portland, Oregon, Egyesült Államok, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Egyesült Államok, 97225
- Providence Saint Vincent Medical Center
-
Redmond, Oregon, Egyesült Államok, 97756
- Saint Charles Health System-Redmond
-
-
Pennsylvania
-
Chadds Ford, Pennsylvania, Egyesült Államok, 19317
- Christiana Care Health System-Concord Health Center
-
Philadelphia, Pennsylvania, Egyesült Államok, 19104
- University of Pennsylvania/Abramson Cancer Center
-
Pittsburgh, Pennsylvania, Egyesült Államok, 15232
- University of Pittsburgh Cancer Institute (UPCI)
-
-
Texas
-
Bryan, Texas, Egyesült Államok, 77802
- Saint Joseph Regional Cancer Center
-
-
Utah
-
Salt Lake City, Utah, Egyesült Államok, 84112
- Huntsman Cancer Institute/University of Utah
-
-
Washington
-
Aberdeen, Washington, Egyesült Államok, 98520
- Providence Regional Cancer System-Aberdeen
-
Bellingham, Washington, Egyesült Államok, 98225
- PeaceHealth Saint Joseph Medical Center
-
Bremerton, Washington, Egyesült Államok, 98310
- Harrison HealthPartners Hematology and Oncology-Bremerton
-
Bremerton, Washington, Egyesült Államok, 98310
- Harrison Medical Center
-
Burien, Washington, Egyesült Államok, 98166
- Highline Medical Center-Main Campus
-
Centralia, Washington, Egyesült Államok, 98531
- Providence Regional Cancer System-Centralia
-
Edmonds, Washington, Egyesült Államok, 98026
- Swedish Cancer Institute-Edmonds
-
Enumclaw, Washington, Egyesült Államok, 98022
- Saint Elizabeth Hospital
-
Everett, Washington, Egyesült Államok, 98201
- Providence Regional Cancer Partnership
-
Federal Way, Washington, Egyesült Államok, 98003
- Saint Francis Hospital
-
Issaquah, Washington, Egyesült Államok, 98029
- Swedish Cancer Institute-Issaquah
-
Kennewick, Washington, Egyesült Államok, 99336
- Kadlec Clinic Hematology and Oncology
-
Lacey, Washington, Egyesült Államok, 98503
- Providence Regional Cancer System-Lacey
-
Lakewood, Washington, Egyesült Államok, 98499
- Saint Clare Hospital
-
Longview, Washington, Egyesült Államok, 98632
- PeaceHealth Saint John Medical Center
-
Poulsbo, Washington, Egyesült Államok, 98370
- Harrison HealthPartners Hematology and Oncology-Poulsbo
-
Seattle, Washington, Egyesült Államok, 98107
- Swedish Medical Center-Ballard Campus
-
Seattle, Washington, Egyesült Államok, 98122
- Swedish Medical Center-First Hill
-
Seattle, Washington, Egyesült Államok, 98104
- Pacific Gynecology Specialists
-
Seattle, Washington, Egyesült Államok, 98122-5711
- Swedish Medical Center-Cherry Hill
-
Sedro-Woolley, Washington, Egyesült Államok, 98284
- PeaceHealth United General Medical Center
-
Shelton, Washington, Egyesült Államok, 98584
- Providence Regional Cancer System-Shelton
-
Tacoma, Washington, Egyesült Államok, 98405
- Franciscan Research Center-Northwest Medical Plaza
-
Vancouver, Washington, Egyesült Államok, 98664
- PeaceHealth Southwest Medical Center
-
Walla Walla, Washington, Egyesült Államok, 99362
- Providence Saint Mary Regional Cancer Center
-
Yelm, Washington, Egyesült Államok, 98597
- Providence Regional Cancer System-Yelm
-
-
Wisconsin
-
Chippewa Falls, Wisconsin, Egyesült Államok, 54729
- Marshfield Clinic-Chippewa Center
-
Eau Claire, Wisconsin, Egyesült Államok, 54701
- Marshfield Medical Center-EC Cancer Center
-
Ladysmith, Wisconsin, Egyesült Államok, 54848
- Marshfield Clinic - Ladysmith Center
-
Marshfield, Wisconsin, Egyesült Államok, 54449
- Marshfield Medical Center-Marshfield
-
Minocqua, Wisconsin, Egyesült Államok, 54548
- Marshfield Clinic-Minocqua Center
-
Rice Lake, Wisconsin, Egyesült Államok, 54868
- Marshfield Medical Center-Rice Lake
-
Stevens Point, Wisconsin, Egyesült Államok, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Wausau, Wisconsin, Egyesült Államok, 54401
- Marshfield Clinic-Wausau Center
-
Weston, Wisconsin, Egyesült Államok, 54476
- Marshfield Medical Center - Weston
-
Wisconsin Rapids, Wisconsin, Egyesült Államok, 54494
- Marshfield Clinic - Wisconsin Rapids Center
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Leírás
Inclusion Criteria:
-
Patient must have locally advanced unresectable stage IIIC or stage IV melanoma
-
Patient must have BRAF V600E or BRAF V600K tumor genotype based on a Clinical Laboratory Improvement Act (CLIA) approved assay
-
Patient must have serum LDH > Upper limit of normal per institution standards
-
Patient must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Baseline measurements of sites of disease must be obtained within 3 weeks prior to study randomization
-
Patient must have been treated with prior immune checkpoint inhibitor therapy (anti PD-1 antibody, anti-CTLA-4 antibody or a combination regimen including either or both agents) either in the adjuvant or metastatic setting. Patient may have received investigational agents in combination with standard therapy, as long as it was adhering to the timeframes below
- Patient must have discontinued active immunotherapy (IL-2, interferon, anti-CTLA-4 antibody, anti-PD-1 antibody etc.) or chemotherapy at least 4 weeks prior to randomization
- Patient must have discontinued any oral targeted therapy at least 2 weeks prior to randomization
-
Patient may have been treated with prior adjuvant therapy including combined BRAF and MEK inhibitor therapy. Patients will be eligible if they tolerated this therapy and did not discontinue the therapy due to toxicity AND >= 6 months have elapsed since the end of adjuvant BRAF and MEK inhibition.
-
Patient may have been treated with prior chemotherapy or radiation therapy
-
Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
-
All females of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy.
-
Women of childbearing potential and sexually active males must not expect to conceive or father children by using accepted and effective method(s) of contraception or abstaining from sexual intercourse for the duration of their participation in the study and for 4 months after the last dose of protocol treatment
-
Patient must have recovered from clinically significant reversible toxicities from previous treatment prior to randomization. Abnormal laboratory values may be grade 1, as long as they meet the eligibility criteria for organ and marrow function
-
Patient must be able to swallow and retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels
-
Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
-
Absolute neutrophil count >= 1,500/mcL (obtained =< 14 days prior to protocol randomization)
-
Platelets >= 100,000/mcL (obtained =< 14 days prior to protocol randomization)
-
Total bilirubin =< institutional upper limit of normal (ULN) (obtained =< 14 days prior to protocol randomization)
-
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3.0 x institutional ULN (obtained =< 14 days prior to protocol randomization)
-
Creatinine =< 1.5 x institutional ULN (obtained =< 14 days prior to protocol randomization)
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Patient with asymptomatic new or progressive brain metastases (active brain metastases) are eligible if the treating physician determines that CNS specific treatment is not required
- NOTE: Patient with treated brain metastases are eligible. No brain imaging is required, however, 1 week must elapse after gamma knife therapy. Patient treated with whole brain radiation that have been stable for 2 months are eligible. Patient are excluded if they have leptomeningeal disease or metastases causing spinal cord compression that are symptomatic or untreated or not stable (documented by imaging) for at least 3 months or requiring corticosteroids. Patients on a stable dose of corticosteroids for at least 1 month or who have been off of corticosteroids for at least 1 week are eligible
Exclusion Criteria:
-
Receiving any other investigational anticancer therapy during the period on study or the 4 weeks prior to randomization
-
Patients received BRAF and MEK inhibitor therapy in the metastatic setting
-
Patients who are experiencing an objective partial response to immunotherapy at the time of study enrollment
-
Pregnant or breast-feeding; due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. A female of childbearing potential is defined as any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
-
A history of interstitial lung disease (ILD) or chronic pneumonitis
- NOTE: If there is radiographic evidence of ILD that is clinically insignificant and asymptomatic, the patient would be eligible
-
Porphyria or psoriasis due to risk of disease exacerbation unless the disease is well controlled and they are under the care of a specialist for the disorder who agrees to monitor the patient for exacerbations
-
Previously documented retinal vein occlusion
-
A history or evidence of increased cardiovascular risk including:
- Left ventricular ejection fraction (LVEF) < institutional lower limit of normal measured within 14 days prior to randomization
- A QT interval corrected for heart rate using the Bazett's formula >= 480 msec
- Current clinically significant uncontrolled arrhythmias. Exception: Patients with controlled atrial fibrillation for > 30 days prior to randomization are eligible
- Acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months prior to randomization
- Abnormal cardiac valve morphology (>= grade 2) documented by echocardiogram unless a cardiologist concludes the valve abnormality is not clinically significant. Patients with grade 1 abnormalities (i.e., mild regurgitation/stenosis) are eligible
- Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
-
Serious concurrent infection or medical illness, including psychiatric disorders, which would jeopardize the ability of the patient to receive the treatment outlined in this protocol with reasonable safety
-
Receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents). Radiotherapy delivered to palliate pain is allowed as long as it is not targeting a lesion that meets RECIST criteria for progression. Radiation therapy to the surgical bed with gamma knife radiotherapy while on treatment during the first cycle is allowed for small volume surgically resected brain metastases. Gamma knife radiotherapy for known active, asymptomatic small volume central nervous system (CNS) lesions may be performed during the first cycle while on study. Radiotherapy for new CNS lesions identified beyond the first cycle is not allowed on study
-
Immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to study drug, or excipients or to dimethyl sulfoxide (DMSO)
-
Prior cytochrome P450 enzyme -inducing anticonvulsant drugs (extended-interval aminoglycoside dosing [EIADs]) (i.e. phenytoin, carbamazepine, phenobarbital, primidone or oxcarbazepine) within 4 weeks prior to randomization
-
Current use of a prohibited medication described in the protocol due to potential drug-drug interaction
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Kezelés
- Kiosztás: Véletlenszerűsített
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Kettős
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
|---|---|
|
Kísérleti: Arm A (dabrafenib, trametinib, hydroxychloroquine)
Patients receive dabrafenib mesylate PO BID, trametinib dimethyl sulfoxide PO QD, and hydroxychloroquine sulfate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. |
Given PO
Más nevek:
Given PO
Más nevek:
Given PO
Más nevek:
|
|
Aktív összehasonlító: Arm B (dabrafenib, trametinib, placebo)
Patients receive dabrafenib mesylate PO BID, trametinib dimethyl sulfoxide PO QD, and placebo PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. |
Given PO Given PO
Más nevek:
Given PO
Más nevek:
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
One-year Progression-free Survival Rate
Időkeret: Assessed every 2 months until 6 months after completion of study treatment, up to 1 year
|
Progression-free survival is defined as the time from randomization to progression or death, whichever occurs first. Progression is defined as appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions, or at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. One-year progression-free survival rate is estimated from the Kaplan-Meier progression-free survival curve. |
Assessed every 2 months until 6 months after completion of study treatment, up to 1 year
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Progression-free Survival
Időkeret: Assessed every 2 months until 6 months after completion of study treatment, up to 3 years
|
Progression-free survival is defined as the time from randomization to progression or death, whichever occurs first. Progression is defined as appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions, or at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. |
Assessed every 2 months until 6 months after completion of study treatment, up to 3 years
|
|
Proportion of Patients With Best Overall Response
Időkeret: Assessed every 2 months until 6 months after completion of study treatment, up to 3 years
|
Best overall response is defined as either complete response or partial response. Complete response is defined as disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. Partial response is defined as persistence of one or more non-target lesion(s) and at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. |
Assessed every 2 months until 6 months after completion of study treatment, up to 3 years
|
|
Proportion of Patients With Complete Response
Időkeret: Assessed every 2 months until 6 months after completion of study treatment, up to 3 years
|
Complete response is defined as disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. |
Assessed every 2 months until 6 months after completion of study treatment, up to 3 years
|
|
Adverse Event Rate
Időkeret: Assessed every 4 weeks while on treatment and for 30 days after the end of treatment, up to 3 years
|
Proportion of patients with treatment-related adverse events of grade 3 or higher. |
Assessed every 4 weeks while on treatment and for 30 days after the end of treatment, up to 3 years
|
|
Overall Survival
Időkeret: Assessed every 2 months until 6 months after completion of study treatment, up to 3 years
|
Overall survival is defined as the time from randomization to death or date last known alive. |
Assessed every 2 months until 6 months after completion of study treatment, up to 3 years
|
Együttműködők és nyomozók
Szponzor
Együttműködők
Nyomozók
- Kutatásvezető: Ravi Amaravadi, ECOG-ACRIN Cancer Research Group
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Tényleges)
Elsődleges befejezés (Tényleges)
A tanulmány befejezése (Tényleges)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
További vonatkozó MeSH feltételek
Egyéb vizsgálati azonosító számok
- EA6191
- U10CA180820 (Az Egyesült Államok NIH támogatása/szerződése)
- EA6191 (Egyéb azonosító: CTEP)
- NCI-2020-04552 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- EA6191 (Egyéb azonosító: ECOG-ACRIN Cancer Research Group)
Terv az egyéni résztvevői adatokhoz (IPD)
Tervezi megosztani az egyéni résztvevői adatokat (IPD)?
IPD terv leírása
Individual participant data may be made available upon request as per the ECOG-ACRIN Data Sharing Policy.
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .